Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
64,234.11 +1,240.80 (+1.97%) CMC Crypto 200
1,346.80 -49.73 (-3.56%)
Satellos Bioscience Inc. (0ITA.F)
| Previous close | 0.2780 |
| Open | 0.2660 |
| Bid | 0.3220 x N/A |
| Ask | 0.3720 x N/A |
| Day's range | 0.2660 - 0.2660 |
| 52-week range | 0.1680 - 0.5200 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 36.948M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireSatellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 08, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.
Business WireSatellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
TORONTO, March 27, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted.
Business WireSatellos to Present at Upcoming Virtual Investor Conferences in March and April
TORONTO, March 14, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences:
